Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.

Detaljer

Författare
  • Karolina Szummer
  • Jonas Oldgren
  • Lars Lindhagen
  • Juan Jesus Carrero
  • Marie Evans
  • Jonas Spaak
  • Robert Edfors
  • Stefan H Jacobson
  • Pontus Andell
  • Lars Wallentin
  • Tomas Jernberg
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi
Originalspråkengelska
Sidor (från-till)707-716
TidskriftJAMA: The Journal of the American Medical Association
Volym313
Utgåva nummer7
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa